Cargando…

Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11

Detalles Bibliográficos
Autores principales:	Mehrling, Thomas, Soltis, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640681/ https://www.ncbi.nlm.nih.gov/pubmed/31544883 http://dx.doi.org/10.3390/antib7030032

Ejemplares similares

Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy
por: Mehrling, Thomas, et al.
Publicado: (2018)

Correction: Verkade, J.M.M.; et al. A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates. Antibodies 2018, 7, 12
por: Verkade, Jorge M. M., et al.
Publicado: (2018)

Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones
por: Bahou, Calise, et al.
Publicado: (2018)

Antibody-Drug Conjugates: Possibilities and Challenges
por: Nejadmoghaddam, Mohammad-Reza, et al.
Publicado: (2019)

Computational Construction of Antibody–Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker
por: Filntisi, Arianna, et al.
Publicado: (2014)

Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
por: Kamath, Amrita V., et al.
Publicado: (2015)

Targeting cancer with antibody-drug conjugates: Promises and challenges
por: Dean, Alexis Q., et al.
Publicado: (2021)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

A Single-Step Chemoenzymatic Reaction for the Construction of Antibody–Cell Conjugates
por: Li, Jie, et al.
Publicado: (2018)

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
por: Wu, Mo, et al.
Publicado: (2022)

Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry
por: Akkapeddi, Padma, et al.
Publicado: (2016)

Antibody conjugation and formulation
por: Alves, Nathan J
Publicado: (2019)

Correction to Kahane et al. (2018)
Publicado: (2018)

Correction to Bratt et al. (2018)
Publicado: (2018)

Correction to Doherty et al. (2018)
Publicado: (2019)

Correction to Mok et al. (2018)
Publicado: (2019)

Correction to Machner et al. (2018)
Publicado: (2019)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

Antibodies to watch in 2018
por: Kaplon, Hélène, et al.
Publicado: (2018)

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
por: Lu, Guolan, et al.
Publicado: (2020)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Automated optimisation of solubility and conformational stability of antibodies and proteins
por: Rosace, Angelo, et al.
Publicado: (2023)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

pH and NaCl Optimisation to Improve the Stability of Gold and Silver Nanoparticles’ Anti-Zearalenone Antibody Conjugates for Immunochromatographic Assay
por: Shahjahan, Thasmin, et al.
Publicado: (2023)

Reply to Brandt et al., “Antibodies to Nucleocapsid Are Not Diagnostic for Long COVID”
por: Fogh, Kamille, et al.
Publicado: (2023)

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

Masthead: (Global Challenges 11/2018)
Publicado: (2018)

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
por: Zhang, Xinling, et al.
Publicado: (2022)

Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates
por: Adhikari, Ajeeth, et al.
Publicado: (2021)

Acknowledgement to Reviewers of Antibodies in 2018
Publicado: (2019)

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2022)

Buchbesprechung zu Immediatszeitungsberichten (Stöber et al. 2018 und Hoppe et al. 2020)
por: Wilke, Jürgen
Publicado: (2020)

Assessment and optimisation of normalisation methods for dual-colour antibody microarrays
por: Sill, Martin, et al.
Publicado: (2010)

Proposal of Lentzea deserti (Okoro et al. 2010) Nouioui et al. 2018 as a later heterotypic synonym of Lentzea atacamensis (Okoro et al. 2010) Nouioui et al. 2018 and an emended description of Lentzea atacamensis
por: Ping, Mo, et al.
Publicado: (2021)

Editor’s note on correction to Crawley et al. (2018)
por: Brown, Nick
Publicado: (2019)

Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”
por: Wasserman, Matt, et al.
Publicado: (2019)

Effect of lyophilization on HRP–antibody conjugation: an enhanced antibody labeling technology
por: Regidi, Saikant, et al.
Publicado: (2018)

Enzyme-Based Labeling Strategies for Antibody–Drug Conjugates and Antibody Mimetics
por: Falck, Georg, et al.
Publicado: (2018)

Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates
por: Abdollahpour-Alitappeh, Meghdad, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s9flj0qgid43j577snlg4svvhr